2,230
Participants
Start Date
October 25, 2021
Primary Completion Date
March 1, 2024
Study Completion Date
March 31, 2026
Ticagrelor
Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
Dabigatran Etexilate
Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
Aspirin
Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
Clopidogrel
Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
RECRUITING
Cardiac lntensive Care Unit, First Department of Cardiology, University Clinical Centre in Gdańsk, Gdansk
Medical University of Warsaw
OTHER
Nicolaus Copernicus University
OTHER
National Institute of Cardiology, Warsaw, Poland
OTHER
Military Institute od Medicine National Research Institute
OTHER
Bielanski Hospital
OTHER
Medical University of Silesia
OTHER
Poznan University of Medical Sciences
OTHER
University of Opole, Poland
UNKNOWN
Medical University of Łódź
OTHER
Voivodeship Hospital, Kielce, Poland
UNKNOWN
Voivode Specialist Hospital in Olsztyn, Poland
UNKNOWN
Medical University of Lublin
OTHER
Pomeranian Medical University Szczecin
OTHER
Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
OTHER
Medical University of Gdansk
OTHER